



## Current Frames on Cardiotoxicology of New and Old Anticancer Drugs

Guest Editor:

**Prof. Dr. Vera Marisa Costa**

UCIBIO, REQUIMTE, Laboratory  
of Toxicology, Faculty of  
Pharmacy, University of Porto,  
Rua de Jorge Viterbo Ferreira,  
228, 4050-313 Porto, Portugal

Deadline for manuscript  
submissions:

**closed (8 May 2024)**

### Message from the Guest Editor

The incidence of cancer is growing worldwide, and it is estimated to grow even more in the coming decades. Nonetheless, the life expectancy of cancer patients is improving, due to the combination of old and new therapies and early diagnosis. Still, the cardiotoxicity of anticancer therapies is a leading cause of death and morbidity in cancer patients, making cardio-oncology a focal clinical and scientific field at present. Therefore, a major future challenge in cardiovascular medicine lies in understanding the molecular basis of cardiotoxicity of anticancer therapies, paving the way to the identification of more efficient diagnostic and therapeutic tools or even of genetic determinants of patients' susceptibility.

It is for this reason that this Special Issue aims to bring together the latest findings in the field of cardio-oncology, involving cell-based studies, preclinical and clinical studies, case reports, and reviews that aim to identify novel mechanisms underlying cardiac remodeling and dysfunction and prompting new pharmacological and non-pharmacological therapeutic solutions.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)